Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study

BACKGROUND: Adjuvant chemotherapy is the standard of care in high-risk early breast cancer patients. Dose-dense should be the preferred schedule of administration. However, its long-term benefit is unknown. METHODS: In the Italian multicentre Phase 3 randomised MIG-1 trial, node-positive and high-ri...

Descripción completa

Detalles Bibliográficos
Autores principales: Blondeaux, Eva, Lambertini, Matteo, Michelotti, Andrea, Conte, Benedetta, Benasso, Marco, Dellepiane, Chiara, Bighin, Claudia, Pastorino, Simona, Levaggi, Alessia, Alonzo, Alessia D’, Poggio, Francesca, Buzzatti, Giulia, Molinelli, Chiara, Fregatti, Piero, Bertoglio, Sergio, Boccardo, Francesco, Del Mastro, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251109/
https://www.ncbi.nlm.nih.gov/pubmed/32231293
http://dx.doi.org/10.1038/s41416-020-0816-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251109/
https://www.ncbi.nlm.nih.gov/pubmed/32231293
http://dx.doi.org/10.1038/s41416-020-0816-8

Ejemplares similares